The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need
New discoveries are a critical priority for the pharmaceutical industry. However, the use of fixed incremental cost-effectiveness (ICER) thresholds for health technology assessment (HTA) may compromise incentives to innovate and affect future treatment options. This paper highlights the impact of ge...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2016-10-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9838 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860334031536128 |
|---|---|
| author | Pierre-Alexandre Dionne Farzad Ali Mendel Grobler |
| author_facet | Pierre-Alexandre Dionne Farzad Ali Mendel Grobler |
| author_sort | Pierre-Alexandre Dionne |
| collection | DOAJ |
| description | New discoveries are a critical priority for the pharmaceutical industry. However, the use of fixed incremental cost-effectiveness (ICER) thresholds for health technology assessment (HTA) may compromise incentives to innovate and affect future treatment options. This paper highlights the impact of generic drug price policies on pharmaceutical innovation in the context of fixed ICER thresholds and proposes a new consideration for the cost-effectiveness analysis (CEA).
There is a direct causal relationship between HTA and the market price of a drug; in jurisdictions where HTA agencies apply fixed ICER thresholds as an important reimbursement listing criterion, the incremental cost of a new drug is expected to be proportional to its incremental benefit over the comparator. However, the comparator price is subject to market forces or sudden policies and may change markedly affecting the cost-effectiveness assessment (e.g. where the comparator patent has expired). Since recent generic price regulations increased the price gap between drugs’ generic and patented versions, it is harder to achieve a sufficient level of incremental benefits in order to offset incremental prices of new treatments. Consequently, even promising drugs may have challenges to show attractive ICERs and research and development (R&D) investments may become unattractive in certain disease area.
In order to promote innovation in therapeutic fields with unmet medical needs, a compromise would be to include the comparator’s patented price in the CEA instead of the generic drug. By identifying the relevant disease areas, decision makers and HTA authorities could therefore convey the importance of investing in these therapeutic areas to manufacturers. |
| format | Article |
| id | doaj-art-3cf9115105de42aa9a59c9d921823c6e |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2016-10-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-3cf9115105de42aa9a59c9d921823c6e2025-02-10T16:12:28ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362016-10-0131The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical NeedPierre-Alexandre DionneFarzad AliMendel GroblerNew discoveries are a critical priority for the pharmaceutical industry. However, the use of fixed incremental cost-effectiveness (ICER) thresholds for health technology assessment (HTA) may compromise incentives to innovate and affect future treatment options. This paper highlights the impact of generic drug price policies on pharmaceutical innovation in the context of fixed ICER thresholds and proposes a new consideration for the cost-effectiveness analysis (CEA). There is a direct causal relationship between HTA and the market price of a drug; in jurisdictions where HTA agencies apply fixed ICER thresholds as an important reimbursement listing criterion, the incremental cost of a new drug is expected to be proportional to its incremental benefit over the comparator. However, the comparator price is subject to market forces or sudden policies and may change markedly affecting the cost-effectiveness assessment (e.g. where the comparator patent has expired). Since recent generic price regulations increased the price gap between drugs’ generic and patented versions, it is harder to achieve a sufficient level of incremental benefits in order to offset incremental prices of new treatments. Consequently, even promising drugs may have challenges to show attractive ICERs and research and development (R&D) investments may become unattractive in certain disease area. In order to promote innovation in therapeutic fields with unmet medical needs, a compromise would be to include the comparator’s patented price in the CEA instead of the generic drug. By identifying the relevant disease areas, decision makers and HTA authorities could therefore convey the importance of investing in these therapeutic areas to manufacturers.https://doi.org/10.36469/9838 |
| spellingShingle | Pierre-Alexandre Dionne Farzad Ali Mendel Grobler The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need Journal of Health Economics and Outcomes Research |
| title | The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need |
| title_full | The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need |
| title_fullStr | The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need |
| title_full_unstemmed | The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need |
| title_short | The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need |
| title_sort | impact of recent generic drug price policies on pharmaceutical innovation a theoretical rationale and proposal of a method supporting innovation in areas of unmet medical need |
| url | https://doi.org/10.36469/9838 |
| work_keys_str_mv | AT pierrealexandredionne theimpactofrecentgenericdrugpricepoliciesonpharmaceuticalinnovationatheoreticalrationaleandproposalofamethodsupportinginnovationinareasofunmetmedicalneed AT farzadali theimpactofrecentgenericdrugpricepoliciesonpharmaceuticalinnovationatheoreticalrationaleandproposalofamethodsupportinginnovationinareasofunmetmedicalneed AT mendelgrobler theimpactofrecentgenericdrugpricepoliciesonpharmaceuticalinnovationatheoreticalrationaleandproposalofamethodsupportinginnovationinareasofunmetmedicalneed AT pierrealexandredionne impactofrecentgenericdrugpricepoliciesonpharmaceuticalinnovationatheoreticalrationaleandproposalofamethodsupportinginnovationinareasofunmetmedicalneed AT farzadali impactofrecentgenericdrugpricepoliciesonpharmaceuticalinnovationatheoreticalrationaleandproposalofamethodsupportinginnovationinareasofunmetmedicalneed AT mendelgrobler impactofrecentgenericdrugpricepoliciesonpharmaceuticalinnovationatheoreticalrationaleandproposalofamethodsupportinginnovationinareasofunmetmedicalneed |